시간 외 거래: 1.95 0.03 +1.56%

Prokidney Corp (PROK)

Prokidney Corp 주식(PROK)의 최신 뉴스

Prokidney Corp (PROK)

Prokidney Corp 주식(PROK)의 최신 뉴스

Recent Insider Activity Suggests Potential Gains for ProKidney Corp (PROK) - Knox Daily

ProKidney (NASDAQ:PROK) Coverage Initiated by Analysts at JPMorgan Chase & Co. - MarketBeat

An In-Depth Look at ProKidney Corp Inc. (PROK) Price Performance During Market Crashes - The InvestChronicle

ProKidney Corp (PROK)’s Day in Review: Closing at 1.86, Down by -8.82 - The Dwinnex

JPMorgan starts ProKidney stock coverage with Neutral rating - Investing.com

How does ProKidney Corp (PROK) change from a tortoise to a hare? - SETE News

Insider Selling: Weber Darin J., ProKidney Corp [PROK] Chief Regulatory Officer divested 16,412 shares - Knox Daily

Insiders Re-Evaluate Their US$54.7m Stock Purchase As ProKidney Falls To US$659m - Simply Wall St

ProKidney Corp (PROK) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle

Is it possible to buy ProKidney Corp(PROK) shares at a good price now? - US Post News

Examining the Potential Price Growth of ProKidney Corp (PROK) - Knox Daily

Investor’s Toolkit: Key Ratios for Assessing ProKidney Corp (PROK)’s Performance - The Dwinnex

ProKidney revises Phase 3 program for lead asset - MSN

Reviewing LadRx (OTCMKTS:CYTR) and ProKidney (NASDAQ:PROK) - Defense World

ProKidney (NASDAQ:PROK) Sees Unusually-High Trading Volume - Defense World

ProKidney Corp. (NASDAQ:PROK) Insider Darin J. Weber Sells 16,412 Shares - MarketBeat

ProKidney executive sells $41,030 in company stock By Investing.com - Investing.com South Africa

ProKidney executive sells $41,030 in company stock By Investing.com - Investing.com Australia

ProKidney executive sells $41,030 in company stock - Investing.com India

ProKidney executive sells $41,030 in company stock - Investing.com

ProKidney executive sells $41,030 in company stock By Investing.com - Investing.com UK

ProKidney (NASDAQ:PROK) Shares Down 6.7% - MarketBeat

Propel Hits 52-Week High on KOHO Link - Baystreet.ca

Propel Holdings Inc. - Baystreet.ca

Wall Street Analyst Initiated ProKidney Corp [PROK]. What else is Wall St. saying - The DBT News

ProKidney Corp [PROK] stock for 2,065 USD was sold by Weber Darin J. - Knox Daily

ProKidney (NASDAQ:PROK) Sees Strong Trading Volume - MarketBeat

PROK’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle

Stocks to Watch: Steelcase, Progyny, America's Car-Mart, Exicure - MarketWatch

ProKidney Corp (PROK) stock analysis: A simple moving average approach - US Post News

Potential Price Increase for ProKidney Corp (PROK) After Recent Insider Activity - Knox Daily

A History of Outperforming Analyst Forecasts and Beating the Odds: ProKidney Corp (PROK) - SETE News

Financial Metrics Exploration: Understanding ProKidney Corp (PROK) Through Ratios - The Dwinnex

ProKidney (NASDAQ:PROK) Shares Gap Down to $2.38 - MarketBeat

ProKidney - The Pharma Letter

ProKidney (NASDAQ:PROK) Shares Down 3.3% - MarketBeat

ProKidney (NASDAQ:PROK) Now Covered by Analysts at Guggenheim - Defense World

Investing in ProKidney Corp (PROK) Is Getting More Attractive - Knox Daily

ProKidney (NASDAQ:PROK) Shares Gap Up to $2.39 - MarketBeat

ProKidney (NASDAQ:PROK) Earns Buy Rating from Analysts at Guggenheim - MarketBeat

Guggenheim highlights ProKidney stock upside in addressing unmet needs for CKD patients - Investing.com Canada

Guggenheim Initiates Coverage of ProKidney (PROK) with Buy Recommendation - Nasdaq

Guggenheim highlights ProKidney stock upside in addressing unmet needs for CKD patients - Investing.com

ProKidney updates on rilparencel’s registrational path to potential US approval - The Pharma Letter

ProKidney (NASDAQ:PROK) Trading 6% Higher - MarketBeat

ProKidney Suspends One of Its Two Phase 3 Kidney Cell Therapy Trials - DocWire News

ProKidney (NASDAQ:PROK) Price Target Lowered to $3.00 at Bank of America - Defense World

ProKidney (NASDAQ:PROK) Shares Gap Down on Analyst Downgrade - Defense World

ProKidney drops Phase III CKD study to focus on US market and save up to $175m - Clinical Trials Arena

BofA cuts ProKidney shares target as cash shortfall raises risksBofA - Investing.com

ProKidney drops Phase III CKD study to focus on US market and save up to $175m - Yahoo Finance

ProKidney drops Phase III CKD study to focus on US market and save up to $175m - Pharmaceutical Technology

ProKidney (NASDAQ:PROK) Shares Gap Down After Analyst Downgrade - MarketBeat

Regenerative medicine institute names former ProKidney CEO Bertram to key position - Winston-Salem Journal

ProKidney discontinues non-US clinical trial step; expected savings up to $175 million - Greensboro News & Record

ProKidney discontinues non-US clinical trial step; expected savings up to $175 million - Winston-Salem Journal

ProKidney (NASDAQ:PROK) PT Lowered to $3.00 at Bank of America - MarketBeat

ProKidney price target lowered to $3 from $4 at BofA - TipRanks

BofA cuts ProKidney shares target as cash shortfall raises risksBofA By Investing.com - Investing.com UK

ProKidney shares hold Buy rating, $5 target amid trial update - Investing.com

ProKidney refocuses on US market for kidney therapy trial - Investing.com India

symbol__ Stock Quote Price and Forecast - CNN

ProKidney refocuses on US market for kidney therapy trial By Investing.com - Investing.com Australia

ProKidney stock slips on changed lead program (NASDAQ:PROK) - Seeking Alpha

ProKidney halts one CKD cell therapy phase 3 trial considered surplus to FDA approval - Fierce Biotech

ProKidney refocuses on US market for kidney therapy trial - Investing.com

ProKidney: Investor Update and Phase 3 Program Progress - TipRanks

ProKidney to discontinue PROACT 2, focus resources on PROACT 1 - TipRanks

ProKidney Announces Strategic Updates to its Phase 3 - GlobeNewswire

Prokidney Announces Strategic Updates to Its Phase 3 Program to Accelerate Rilparencel?s Registrational Path to Potential Approval in the U.S - Marketscreener.com

Former ProKidney CEO will lead regenerative medicine institute's ecosystem, NSF efforts - The Business Journals

PROK과 유사한 종목